BioSource Shareholders OK Slate of Directors

At its annual meeting earlier this month, shareholders for BioSource International of Camarillo approved the company’s nominated slate of directors.

Shareholders also endorsed the selection of the firm’s independent public accountants, KPMG Peat Marwick LLP of Woodland Hills.

The board of directors of the company is now composed of James H. Chamberlain, chairman; Leonard M. Hendrickson; David J. Moffa, PhD; John R. Overturf; and Robert D. Weist.

Shareholders also authorized certain actions to affect the delisting of the company on the Vancouver Stock Exchange.

Two remaining issues did not receive sufficient votes to be approved: an amendment to the company’s Certificate of Incorporation to establish a classified board of directors and limit certain stockholder actions, and an amendment to the company’s stock incentive plan that would increase the number of shares available.

Because both these issues are receiving a strong positive response from shareholders based on the number of votes received as of July 1, BioSource is giving shareholders an additional 30 days to cast their votes.

BioSource is a supplier of immunological reagents and test kits used in biomedical research. For the year ended Dec. 31, 1995, BioSource reported earnings of $1.16 million, or 20 cents per share, on revenues of $8.6 million.